End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.2 CNY | +2.27% | -5.02% | -14.86% |
Mar. 18 | Dashenlin Pharmaceutical to Buy Back Up to 200 Million Yuan Shares | MT |
Mar. 05 | Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.86% | 3.33B | C- | ||
-32.21% | 15.27B | B- | ||
-31.97% | 10.84B | B | ||
-30.42% | 6.06B | B | ||
+8.14% | 6.04B | C | ||
-11.41% | 5.86B | C+ | ||
-0.88% | 4.71B | D- | ||
+52.19% | 4.29B | - | C | |
-12.31% | 3.61B | B | ||
-6.93% | 3.01B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603233 Stock
- Ratings DaShenLin Pharmaceutical Group Co., Ltd.